HC Wainwright set a $5.00 price target on Veru (NASDAQ:VERU) in a research note issued to investors on Thursday. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Veru from a hold rating to a buy rating and set a $2.50 target price for the company in a research report on Wednesday, September 27th. ValuEngine raised shares of Veru from a sell rating to a hold rating in a research report on Thursday, August 31st.

Veru (NASDAQ VERU) traded up $0.02 during trading hours on Thursday, reaching $1.24. 119,200 shares of the company were exchanged, compared to its average volume of 98,261. Veru has a 12 month low of $0.90 and a 12 month high of $3.00.

ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/hc-wainwright-analysts-give-veru-veru-a-5-00-price-target/1771365.html.

About Veru

Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.